Chiara Nainkwi Fenangi

Ms. Chiara Nainkwi Fenangi

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2026 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
CFChiara Nainkwi Fenangi
Chiara Nainkwi Fenangi
HGHazar Gözgöz
Hazar Gözgöz
TETuğba Şan Erkoç
Tuğba Şan Erkoç
MAMine Arayıcı
Mine Arayıcı
ÖDÖzlem Gürsoy Doruk
Özlem Gürsoy Doruk
Objectives: Although lithium (Li) remains a first-line treatment for bipolar disorder (BD), its exact mechanisms of action are still heavily debated. Because neurosteroid (NS) dysregulation plays a critical role in psychiatric disorders, this study looked into whether some of lithium’s effects are mediated through altering intracellular NS levels. Methods: We assessed the effects of Li (0.5–25 mM) on SH-SY5Y cell viability over 24–72 h using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays. Following this, we measured intracellular NS levels at specific doses and durations via LC-MS/MS. Results: While 0.5–2.5 mM Li treatments preserved cell viability, doses ≥5 mM markedly reduced it (p<0.05). At a 1 mM non-toxic dose (24 h), we noted a significant buildup in pregnenolone, progesterone, 17-OH progesterone, and dehydroepiandrosterone (DHEA) (p<0.05). Conversely, treating cells with 25 mM Li spiked pregnenolone but significantly depleted androstenedione (p<0.05), and it drove up dehydroepiandrosterone sulfate (DHEAS) across all time points. Conclusions: In conclusion, Li distinctly alters neurosteroidogenesis in a dose and time-dependent manner. Although preliminary, these in vitro findings offer remarkable insights, suggesting that NS pathways might mediate lithium’s clinical efficacy, warranting further comprehensive studies.

Verified
Journal Article
Open access
PDF file
ACArda Ceylan
Arda Ceylan
XHXiaozhou Hu
Xiaozhou Hu
THTevfik Hatipoğlu
Tevfik Hatipoğlu
CFChiara Nainkwi Fenangi
Chiara Nainkwi Fenangi
KPKadriye Bahriye Payzin
Kadriye Bahriye Payzin
Can KüçükCan Küçük
Can Küçük
Multiple myeloma (MM) is an incurable hematological malignancy. SOX7, located within the recurrently deleted 8p23.1 region in MM, is suggested to act as a tumor suppressor. We characterized SOX7 through genetic, epigenetic, and functional analyses in MM cell lines. SOX7 was frequently silenced due to deletion and/or promoter hypermethylation. Ectopic SOX7 expression in KMS-18 and MM.1S cell lines caused a progressive decline in SOX7-transduced cells and induced G1 cell cycle arrest and/or apoptosis. Although SOX7 re-expression did not enhance bortezomib efficacy, treatment with the pan-histone deacetylase inhibitor panobinostat induced G1 arrest, promoted apoptosis, and increased SOX7 expression in MM.1S cells. Whole-transcriptome sequencing identified G1/S progression-related Wnt/β-catenin pathway genes as major SOX7-regulated targets, while ChIP-Seq analysis revealed widespread genomic SOX7 occupancy in MM.1S. Flow cytometric analysis of permeabilized bone marrow tumor cells from newly diagnosed and relapsed MM patients demonstrated generally low SOX7 protein expression. Collectively, these results indicate that SOX7 functions as a tumor suppressor in MM, and its inactivation promotes cell cycle progression. The anti-myeloma effects of panobinostat in MM.1S cells may be partially mediated through SOX7 induction.